Sandoz Study Highlights Saving Potential Of Pegfilgrastim Biosimilar
As Healthcare Outcomes Of Generic Copaxone Revealed
Executive Summary
Sandoz has published the results of two studies involving the company’s pegfilgrastim biosimilar and glatiramer acetate generic. For the former, Sandoz observed cost savings could run eventually to tens of millions of dollars per year with patient conversion and expanded access.